
The phase III Clarity AD clinical trial of lecanemab, an amyloid-targeting antibody, showed a small clinical benefit in people with Alzheimer's disease. However, several questions remain regarding the true clinical relevance, safety, and accessibility of lecanemab in this patient population.
Like
Save
Share